Arrowhead Pharmaceuticals spent its earnings week addressing a problem created outside its own business: the first sales signal from Ionis Pharmaceuticals’ Tryngolza in severe hypertriglyceridemia, or sHTG. Ionis reported flat sales of just $9 million for the drug and lowered sales guidance for the year to $50 million, factoring in a slower ramp.
That mattered immediately for Arrowhead because Redemplo has been submitted to the FDA in the same indication. The company said the filing earned entry to the FDA’s Split Real Time Application Review, or STAR, pilot program, which offers drugs that demonstrate an improvement over available therapies a shot at a faster review. Arrowhead is preparing a second quarter launch for Redemplo in sHTG.
The Commercial Picture
Investor concern was direct. Stifel wrote that the Tryngolza sales print was "even worse than what were already low expectations," while Jefferies described the setup for Arrowhead’s impending sHTG launch as tricky.
Arrowhead management rejected the idea that Ionis’ performance changes the thesis. On the company’s Thursday earnings call, CEO Chris Anzalone said, “What we learned from Ionis doesn’t affect our expectation in sHTG at all. I think what we’ve seen from them are some missteps in communication, some missteps in commercial execution, and we don’t expect to have those missteps.” He also said Redemplo should offer a differentiated profile.
The strategic signal is that sHTG now looks less like a demand story and more like an execution test. If Arrowhead is right, a better product profile and tighter launch discipline could still support a large market. If Ionis’ experience reflects structural limits in diagnosis, prescribing, or patient uptake, the category could prove smaller than bullish models assume.
Jefferies has not abandoned the upside case, estimating Redemplo could still reach $2.5 billion in sales, but the firm also said it may take time to disprove the new negative narrative.
The Road Here
Arrowhead has one piece of evidence of its own: fiscal year 2026 was the first year it recorded full sales for Redemplo after the drug’s approval for familial chylomicronemia syndrome in November 2025. The product brought in $6.6 million, a result executives said they were happy with, and management pointed to those early launch results as support for confidence going into sHTG.
Even so, the company’s near-term story is now tied to whether Redemplo can separate itself from the category’s first messy commercial readout. The FDA review path may help with timing, but the bigger issue for investors is whether Arrowhead can show that Ionis’ weak launch was company-specific rather than market-defining.
